In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Tarsus Pharmaceuticals Inc (NASDAQ: TARS) was $58.59 for the day, up 0.02% from the previous closing price of $58.58. In other words, the price has increased by $0.02 from its previous closing price. On the day, 0.86 million shares were traded. TARS stock price reached its highest trading level at $59.76 during the session, while it also had its lowest trading level at $58.05.
Ratios:
Our analysis of TARS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Azamian Bobak R. sold 6,000 shares for $50.00 per share. The transaction valued at 300,000 led to the insider holds 818,106 shares of the business.
Azamian Bobak R. bought 6,000 shares of TARS for $300,000 on Aug 11 ’25. On Jun 17 ’25, another insider, Farrow Jeffrey S, who serves as the insider of the company, sold 13,608 shares for $40.42 each. As a result, the insider received 550,035 and left with 36,704 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2473324032 and an Enterprise Value of 2164627456. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.37 while its Price-to-Book (P/B) ratio in mrq is 7.44. Its current Enterprise Value per Revenue stands at 7.325 whereas that against EBITDA is -22.45.
Stock Price History:
The Beta on a monthly basis for TARS is 0.82, which has changed by 1.0182569 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $58.95, while it has fallen to a 52-week low of $25.82. The 50-Day Moving Average of the stock is 27.60%, while the 200-Day Moving Average is calculated to be 22.96%.
Shares Statistics:
TARS traded an average of 615.92K shares per day over the past three months and 546600 shares per day over the past ten days. A total of 42.21M shares are outstanding, with a floating share count of 38.56M. Insiders hold about 8.65% of the company’s shares, while institutions hold 107.60% stake in the company. Shares short for TARS as of 1755216000 were 7339962 with a Short Ratio of 11.92, compared to 1752537600 on 8208464. Therefore, it implies a Short% of Shares Outstanding of 7339962 and a Short% of Float of 17.979999.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate the current performance of Tarsus Pharmaceuticals Inc (TARS) in the stock market.The consensus estimate for the next quarter is -$0.03, with high estimates of $0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$1.44 and -$1.56 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is $0.03, with 3.0 analysts recommending between $1.39 and -$2.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $118.92M to a low estimate of $109.93M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $48.12MFor the next quarter, 6 analysts are estimating revenue of $131.67M. There is a high estimate of $137.26M for the next quarter, whereas the lowest estimate is $124.24M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $437.18M, while the lowest revenue estimate was $415.16M, resulting in an average revenue estimate of $425.61M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $607.94M in the next fiscal year. The high estimate is $715.08M and the low estimate is $464.91M.
